Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

NCT02503423 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT02503423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02503423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 14, 2015
Completion date
December 31, 2027
Enrollment
253 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, solid tumors